Anti-PD-1 monotherapy may allow the more senior older patients to achieve excellent survival without the risk of added toxicity from combination ICI as their melanoma is more responsive to ICI, and their tolerance of toxicity may be lower. The gene discussed is PDCD1; the disease is melanoma.